Download PDF
Thromb Haemost 1961; 6(02): 270-281
DOI: 10.1055/s-0038-1654560
Originalarbeiten — Original Articles — Travaux Originaux
Schattauer GmbH

Antithrombin II Anticoagulant (Autoprothrombin II-A)[*]

Walter H. Seegers
1   Department of Physiology and Pharmacology, Wayne State University College of Medicine, Detroit, Michigan
,
Orhan N. Ulutin
1   Department of Physiology and Pharmacology, Wayne State University College of Medicine, Detroit, Michigan
› Author Affiliations
Further Information

Publication History

Publication Date:
12 July 2018 (online)

Also available at
    Permissions and Reprints

Summary

Autoprothrombin II-A activity frequently develops when the autoprothrombin II fraction of prothrombin is dried from the frozen state. When the anticoagulant activity develops, the N-terminal amino acid arginine is found, but not when the anticoagulant activity does not develop. The anticoagulant autoprothrombin II-A retarded the conversion of prothrombin to thrombin when three different procoagulants were used; namely, platelet cofactor I, autoprothrombin II, and lung extract. The procoagulant power of the platelet cofactor I is most easily depressed. It is postulated that autoprothrombin II-A activity develops when prothrombin activates and that platelet cofactor I is a receptor of the anticoagulant. In that way the other procoagulants are not ordinarily inhibited by the autoprothrombin II-A. As a further extension of this speculation, attention is brought to the idea that autoprothrombin II-A could be present in certain hemorrhagic diseases. In the PTA patient there is no autoprothrombin II and most likely no autoprothrombin II-A. The close chemical relationship of these two prothrombin derivatives thus may account for the multiple deficiency.

* This work was aided by a grant from the Michigan Heart Association.


 

  • References

  • (1) Seegers W. H, Johnson S. A. Conversion of prothrombin to autoprothrombin II (platelet cofactor II) and its relation to the blood clotting mechanisms. Amer. J. Physiol. 184: 259 1956;
    PubMedSearch in Google Scholar
  • (2) Mammen E. F, Thomas W. R, Seegers W. H. Activation of purified prothrombin to autoprothrombin I or autoprothrombin II (Platelet Cofactor II) or autoprothrombin II-A. Thromb. Diath. haem. 5: 218 1960;
    PubMedSearch in Google Scholar
  • (3) Ulutin O. N, Mammen E. F, Seegers W. H. Purified platelet cofactor I and purified autoprothrombin II in thromboplastin generation test. Thromb. Diath. haem. 5: 456 1961;
    PubMedSearch in Google Scholar
  • (4) Seegers W. H. The purification of prothrombin. Rec. Chem. Progr. 13: 143 1952;
    PubMedSearch in Google Scholar
  • (5) Seegers W. H, Mammen E. F, Lee J. M, Landaburu R. H, Cho M. H, Baker W. J, Shepard R. S. Further studies on the purification of platelet cofactor I. Hemophilia and other Hemorrhagic States. Edited by Brinkhous K. M. 38 Univ. of North Carolina Press; Chapel Hill: 1959
    Search in Google Scholar
  • (6) Seegers W. H, Levine W. G, Shepard R. S. Further studies on the purification of thrombin. Canad. J. Biochem. 36: 603 1958;
    PubMedSearch in Google Scholar
  • (7) Ware A. G, Seegers W. H. Two-stage procedure for the quantitative determination of prothrombin concentration. Amer. J. clin. Path. 19: 471 1949;
    PubMedSearch in Google Scholar
  • (8) Seegers W. H, Smith H. P. Factors which influence the activity of purified thrombin. Amer. J. Physiol. 137: 348 1942;
    PubMedSearch in Google Scholar
  • (9) Mammen E. F, Yoshinari M, Seegers W. H. Platelet cofactors as plasma components of the intrinsic blood clotting mechanism. Thromb. Diath. haem. 5: 38 1960;
    PubMedSearch in Google Scholar
  • (10) Edman P. Preparation of phenyl thiohydantoins from some natural amino acids. Acta chem. scand. 4: 277 1950;
    CrossrefPubMedSearch in Google Scholar
  • (11) Sjöquist J. Paper strip identification of phenyl thiohydantoins. Acta chem. scand. 7: 447 1953;
    CrossrefPubMedSearch in Google Scholar
  • (12) Edman P, Sjöquist J. Identification and semiquantitative determination of phenyl thiohydantoins. Acta chem. scand. 10: 1507 1956;
    CrossrefPubMedSearch in Google Scholar
  • (13) Blombäck B, Yamashina I. On the N-terminal amino acids in fibrinogen and fibrin. Ark. Kemi 12: 299 1958;
    PubMedSearch in Google Scholar
  • (14) Seegers W. H, Casillas G, Shepard R. S, Thomas W. R, Halick P. Some properties of thrombin preparations. Canad. J. Biochem. 37: 776 1959;
    PubMedSearch in Google Scholar
  • (15) Seegers W. H, McClaughry R. I, Fahey J. L. Some properties of purified prothrombin and its activation with sodium citrate. Blood 5: 421 1950;
    PubMedSearch in Google Scholar
  • (16) Graham J. B, Penick G. D, Brinkhous K. M. Utilization of the antihemophilic factor during clotting of canine blood and plasma. Amer. J. Physiol. 164: 710 1951;
    PubMedSearch in Google Scholar
  • (17) Johnson S. A, Rutsky J, Schneider C. L, Seegers W. H. Activation of purified prothrombin with hemophilia plasma. Proc. 4th Internat. Congress Internat. Soc. Hernat. Mar del Plata, Argentina Sept. 20—27, 1952. 373 Grune and Stratton; New York: 1954
    Search in Google Scholar
  • (18) Johnson S. A, Seegers W. H. Studies on the plasma defect in haemophilia. Rev. Hernat. 9: 529 1954;
    PubMedSearch in Google Scholar
  • (19) Johnson S. A, Seegers W. H. Platelet cofactor activity in the hemophilias. Hemophilia and Hemophilioid Diseases. Edited by Brinkhous K. M. 27 Univ. of North Carolina Press; Chapel Hill: 1957
    Search in Google Scholar
  • (20) Wagner R. H, Brinkhous K. M, Penick G. D. Antihemophilic factor: some problems in its study. Hemophilia and other Hemorrhagic States. Edited by Brinkhous K. M. 3 Univ. of North Carolina Press; Chapel Hill: 1959
    Search in Google Scholar
  • (21) Penick G. D. Some factors that influence utilization of antihemophilic activity during clotting. Proc. Soc. exp. Biol. (N. Y.) 96: 277 1957;
    CrossrefPubMedSearch in Google Scholar
  • (22) Johnson S. A, McClaughry R. I, Seegers W. H. J. Mich. med. Soc. 54: 797 1955;
    PubMedSearch in Google Scholar